CymaBay has previously announced positive data from its Phase 2 study of seladelpar in patients with PBC and following successful discussion with the FDA and EMA has advanced into a global Phase 3 registration program. CymaBay is committed to bring this program to successful global approvals and to retain full global rights to launch and commercialize seladelpar for the treatment of PBC. In addition, the unmet medical need and the significant market size of NASH represents a unique opportunity for CymaBay. The Company commenced a Phase 2b Proof of Concept Study in 2018.
LENSA generates certain information provided on this website by compiling and analyzing publicly available data and data from employees/former employees. All company names are the registered trademarks of their original owners. The use of any trade name or trademark does not imply any association with the third-party company. None of the information provided is endorsed in any way by any of the companies mentioned. We do not guarantee the accuracy, currency, or suitability of this information (including regarding demographics or salary estimate) and you are responsible for how you use it. ALL INFORMATION IS PROVIDED “AS IS” AND “WITH ALL FAULTS”. We are not responsible for nor endorse third party content on our website. If you notice any inaccurate information or information you think is proprietary you can email us at [email protected]. See our Terms and Conditions and Community Guidelines for more information.
